Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IceCure Medical
Caesarea, Haifa District, Israelicecure-medical.com ↗
- Ownership
- Public · ICCM
- Development stage
- Commercial
01
Overview
IceCure Medical’s ProSense Cryoablation System uses liquid nitrogen to achieve ultra-cold temperatures that destroy tumor tissue in a minimally invasive procedure. Clinical studies have shown high efficacy, with interim results from the ICE3 trial reporting a recurrence-free rate of approximately 96.91% in breast tumor patients. The system has been adopted globally and supports both office-based and hospital procedures.
- Therapeutic areas
- Oncology
- Modalities
- Device
- Industry
- Therapeutic Medical Devices
02
Financials
- Market cap
- $1.6M
- Total revenue
- $3.4M
- Enterprise value
- $-10.4M
Beyond the preview
Go deeper on IceCure Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IceCure Medical.